SPIRONOLACTONE

被引:77
作者
OCHS, HR
GREENBLATT, DJ
BODEM, G
SMITH, TW
机构
[1] MASSACHUSETTS GEN HOSP,DEPT MED,CLIN PHARMACOL UNIT,BOSTON,MA 02114
[2] PETER BENT BRIGHAM HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115
[3] HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115
[4] UNIV BONN,MED KLIN,D-5300 BONN 1,FED REP GER
关键词
D O I
10.1016/0002-8703(78)90052-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:389 / 400
页数:12
相关论文
共 200 条
[81]  
KARIM A, 1976, CLIN PHARMACOL THER, V19, P177
[82]  
KARIM A, 1976, CLIN PHARMACOL THER, V19, P158
[83]   PHARMACOKINETIC AND METABOLIC FATE OF POTASSIUM CANRENOATE (SC-14266) IN MAN [J].
KARIM, A ;
RANNEY, RE ;
MAIBACH, HI .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (05) :708-&
[84]  
KAUTZSCH G, 1964, THESIS ERFURT
[85]   EXPERIENCE WITH USE OF AN ALDOSTERONE ANTAGONIST IN SELECTED HYPERTENSIVE PATIENTS [J].
KERT, MJ ;
TARR, LW ;
MAXWELL, M ;
FRANKLIN, S ;
GOLD, E ;
OKUN, R .
ANGIOLOGY, 1972, 23 (10) :617-&
[86]  
KLAASSEN CD, 1974, J PHARMACOL EXP THER, V191, P212
[87]  
KLAASSEN CD, 1974, J PHARMACOL EXP THER, V191, P201
[88]  
Kleeberg U R, 1974, Verh Dtsch Ges Inn Med, V80, P1521
[89]   SPIRONOLACTONE AND THIABUTAZIDE IN TREATMENT OF ESSENTIAL HYPERTENSION [J].
KLUMPP, F ;
BRAUN, B ;
KLAUS, D ;
LEMKE, R ;
ZEHNER, J ;
ZOFEL, P .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1975, 100 (12) :577-584
[90]  
KOCZOREK KR, 1969, RENALER TRANSPORT DI, P269